Physician profile
Wonsock Shin
NPI 1821098203
$4,960.33
in general payments reported to CMS, 2019-2025
32 companies · $604 in 2025
The $604 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $899 · 2020: $769 · 2021: $706 · 2022: $632 · 2023: $785 · 2024: $566 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,874 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,874.30 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $823.02 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $647.42 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $481.79 | 2019-2025 | Farxiga, Airsupra |
| Astellas Pharma US INC | $415.89 | 2019-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $393.19 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $358.25 | 2019-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.48 | 2019-2025 | Jardiance, Tradjenta |
| Amarin Pharma, INC. | $225.48 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $152.78 | 2021-2022 | |
| Abbvie INC. | $124.76 | 2021-2025 | Vraylar |
| Merck Sharp & Dohme LLC | $77.40 | 2019-2020 | |
| Allergan, INC. | $76.90 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.97 | 2021-2022 | |
| Bausch Health US, LLC | $72.34 | 2024-2025 | Wellbutrin |
| Biohaven Pharmaceuticals, INC. | $63.07 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $62.31 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $60.46 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $55.09 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $53.83 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $52.49 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $47.11 | 2021-2022 | |
| Biogen, INC. | $46.45 | 2020-2022 | |
| Abbott Laboratories | $36.34 | 2022-2023 | Freestyle Libre 2 |
| Genentech USA, INC. | $33.98 | 2020 | |
| Ibsa Pharma INC. | $33.11 | 2022-2023 | Tirosint, Licart |
| Acorda Therapeutics, INC | $29.42 | 2019 | |
| Scilex Pharmaceuticals INC. | $24.17 | 2025 | |
| Idorsia Pharmaceuticals US INC | $22.28 | 2023 | Quviviq |
| Sumitomo Pharma America, INC. | $18.14 | 2025 | Gemtesa |
| Horizon Therapeutics Plc | $18.14 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $17.35 | 2020 | |
| Glaxosmithkline, LLC. | $15.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wonsock Shin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.